Summit to Present Phase 2 CoDIFy Trial Data Highlighting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016

OXFORD, United Kingdom, May 23, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ: SMMT ), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole’s preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.

Ridinilazole is part of a novel structural class of antibiotics with potential for broad use in the treatment of CDI. As previously reported, in a Phase 2 clinical trial called CoDIFy, ridinilazole demonstrated substantial clinical benefit over vancomycin. The data to be presented at ASM Microbe, including additional results from CoDIFy, further highlight ridinilazole as a highly selective antibiotic for CDI with the potential to treat the initial infection and reduce recurrent disease, the key clinical issue in the treatment of CDI.

All of the poster presentations take place on 20 June 2016 from 12:30-14:30 EDT. Details are as follows:

Session: Monday Late-Breaker Poster Presentations Abstract Number: LB-116 Title: Ridinilazole Preserves Major Components of the Intestinal Microbiota During Treatment of Clostridium difficile Infection Authors: J. Chang, A. Kane, L. McDermott, R. J. Vickers, D. R. Snydman, C. M. Thorpe

Session: Clostridium difficile : Efficacy of New Therapeutic Interventions Abstract Number: MONDAY-440 Title: Ridinilazole (RDZ) for Clostridium difficile Infection (CDI) – Further Data from the CoDIFy Phase 2 Clinical Trial Authors: R. J. Vickers, M. H. Wilcox, D. N. Gerding

Session: Clostridium difficile : Efficacy of New Therapeutic Interventions Abstract Number: MONDAY-441 Title: Ridinilazole for Clostridium difficile Infection (CDI). Reductions in Calprotectin and Lactoferrin During Therapy Authors: Y. Ke, R. Vickers, Y-X. Li

Session: Clostridium difficile : Efficacy of New Therapeutic Interventions Abstract Number: MONDAY-442 Title: Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT19969) Authors: D. R. Snydman, L. A. McDermott, C. M. Thorpe, J. Chang, J. Wick S. T. Walk, R. Vickers

Session: Clostridium difficile : Efficacy of New Therapeutic Interventions Abstract Number: MONDAY-443 Title: Resistance Development Studies with Ridinilazole (RDZ) and Clostridium difficile Authors: D. Hall, C. Pillar, R. Vickers, D. Shinabarger

About C. difficile Infection C. difficile infection is a serious healthcare threat in hospitals, long-term care homes and increasingly the wider community with between 450,000 and 700,000 cases of CDI in the US annually. It is caused by an infection of the colon by the bacterium C. difficile , which produces toxins that cause inflammation, severe diarrhoea and in the most serious cases can be fatal. Patients typically develop CDI following the use of broad-spectrum antibiotics that can cause widespread damage to the natural gastrointestinal (gut) flora and allow overgrowth of C. difficile bacteria. Existing CDI treatments are predominantly broad spectrum antibiotics, and these cause further damage to the gut flora and are associated with high rates of recurrent disease. Recurrent disease is the key clinical issue as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs. The economic impact of CDI is significant with one study estimating annual acute care costs at $4.8 billion in the US.

About Ridinilazole Ridinilazole (previously known as SMT19969) is an orally administered small molecule antibiotic that Summit is developing specifically for the treatment of CDI. In preclinical efficacy studies, ridinilazole exhibited a narrow spectrum of activity and had a potent bactericidal effect against all clinical isolates of C. difficile tested. In a Phase 2 proof of concept trial in CDI patients, ridinilazole showed statistical superiority in sustained clinical response (‘SCR’) rates compared to the standard of care, vancomycin. In this trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy. Ridinilazole has received Qualified Infectious Disease Product (‘QIDP’) designation and has been granted Fast Track designation by the US Food and Drug Administration. The QIDP incentives are provided through the US GAIN Act and include an extension of marketing exclusivity for an additional five years upon FDA approval.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter ( @summitplc ).

For more information, please contact:

Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office)   Tel: +44 (0)1235 443 951   +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson     Tel: +44 (0)20 7148 7900
N+1 Singer (Broker) Aubrey Powell / Jen Boorer       Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications (US media contact) Chris Erdman / Karen Sharma   Tel: +1 781 235 3060 cerdman@macbiocom.com
Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville Tel: +44 (0)20 3709 5700 summit@consilium-comms.com

Forward Looking Statements Any statements in this press release about Summit’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of Summit’s product candidates, the therapeutic potential of Summit’s product candidates, and the timing of initiation, completion and availability of data from clinical trials, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summit’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that Summit makes with the Securities and Exchange Commission including Summit’s Annual Report on Form 20-F for the fiscal year ended January 31, 2016. Accordingly readers should not place undue reliance on forward looking statements or information. In addition, any forward looking statements included in this press release represent Summit’s views only as of the date of this release and should not be relied upon as representing Summit’s views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release.

- END -

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Uncovering Surveillance Pricing: Consumer Watchdog's New Insights

Updated Category News Views 124

Understanding Surveillance Pricing in Today's Market As we continue to navigate the digital landscape, a new and concerning practice has emerged within the retail and e-commerce sectors — surveillance pricing. This strategy allows corporations to charge different prices to consumers for the same item based on their personal data and online behavior, as highlighted by...

Continue Reading
Understanding Voting Rights and Capital at Albion Technology

Updated Category News Views 136

Total Voting Rights and Capital Overview Albion Technology & General VCT PLC In accordance with Disclosure Guidance and Transparency Rule 5.6.1, we at Albion Technology & General VCT PLC are providing key insights into our voting rights and capital structure. Issued Share Capital Details As of the recent update, the issued share capital and voting rights of the Company...

Continue Reading
Hisense Unveils Cutting-Edge Smart Home Solutions at IFA

Updated Category News Views 130

Transforming Everyday Living with Hisense Smart Technology Leading the way in home technology, Hisense recently showcased a range of innovative smart home solutions designed to enhance daily living at the IFA 2024 trade show. As a prominent name in consumer electronics, Hisense is committed to elevating the smart living experience for users worldwide. Hisense's Dedication...

Continue Reading
Jeffs’ Brands Enters Strategic Agreement for Security Tech Expansion

Updated Category News Views 296

Exploring New Horizons: Jeffs’ Brands' Non-Binding MOU The 3D, AI-Powered Technology Screens 25,000 People Per Hour—Without Stopping Them In an exciting development for Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (NASDAQ: JFBR, JFBRW), a leading data-driven e-commerce firm leveraging the Amazon Marketplace, the company has announced its wholly owned...

Continue Reading
Garmin and Global Researchers Unveil Groundbreaking Happiness Study

Updated Category News Views 175

Introduction to the Health and Happiness Study Garmin, known for its innovative technology, has embarked on an exciting journey in collaboration with researchers from prestigious institutions aimed at understanding the intricate relationship between technology, happiness, and wellbeing. This Health and Happiness Study represents a significant step forward in the quest to...

Continue Reading